Your Partner of Choice for Carbohydrates.

GMP Manufacturing

'a complete solution from GMP laboratories to GMP manufacturing'

At our Reading facility we offer full cGMP manufacturing to support phase 1 and phase 2 clinical trials in reactors up to 50 L and operating at temperatures from minus 90 oC to 200 oC. Late phase and commercial production is available at our cGMP facility in New Zealand.


cGMP manufacture is supported by a full analytical capability that includes method development, qualification and validation as well as degradation and stability studies, specification development and full QC testing of all incoming raw materials and intermediates. Our analytical facilities are resourced with qualified equipment which allows us to support all phases of our projects.


See for large-scale synthesis and other manufacturing capabilities.

  • Dextra successfully delivered a number of novel nucleoside, nucleotide and carbohydrate targets for our company in a long standing collaboration, involving highly challenging chemistry and purification and against impressive timelines. The productive and rapid discussions between Dextra’s chemistry, analytical and business development departments and with our company were instrumental towards the completion of the projects. The range of expertise demonstrated by Dextra scientists led to synthetic issues being resolved in a timely manner and their input was key towards the progress achieved at a high level of quality. Dextra possesses a number of highly talented, skilled and dedicated chemists as well as supportive leadership and we have greatly appreciated their contributions. We would thoroughly recommend Dextra to companies who require medicinal chemistry and process development.

    Dr Alistair Stewart, Director CMC , Idenix Pharmaceuticals
  • Galecto Biotech has been very pleased to work with Dextra on a complex carbohydrate chemistry project. Dextra provided excellent service through route scouting, process development and delivery of toxicology and GMP API batches. Communication is open and honest and Galecto Biotech gladly recommends Dextra as a collaboration partner.

    Anders Pederson, Chief Operating Officer , Galecto Biotech
  • DFI has been pleased with Dextra who are a professional and adaptable company with high quality labs and talented staff. The Dextra team were able to resolve a complex reaction impurity profile through complimentary HPLC and IC methods, which contributed to the understanding and scale-up of our process. Communication has always been open and honest through regular teleconferences, meeting and reports. We recommend Dextra as a company to work with for research intended for industrial projects.

    Jonathan Stapley, Chief Technology Officer , DFI Corporation